AR109264A1 - Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 - Google Patents
Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123Info
- Publication number
- AR109264A1 AR109264A1 ARP170101993A ARP170101993A AR109264A1 AR 109264 A1 AR109264 A1 AR 109264A1 AR P170101993 A ARP170101993 A AR P170101993A AR P170101993 A ARP170101993 A AR P170101993A AR 109264 A1 AR109264 A1 AR 109264A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- sequence seq
- polypeptide
- antibody
- Prior art date
Links
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 102000014914 Carrier Proteins Human genes 0.000 abstract 4
- 108091008324 binding proteins Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000052088 human IL3RA Human genes 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305923 | 2016-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109264A1 true AR109264A1 (es) | 2018-11-14 |
Family
ID=56507555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101993A AR109264A1 (es) | 2016-07-18 | 2017-07-17 | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190241657A1 (enExample) |
| EP (1) | EP3484924A1 (enExample) |
| JP (2) | JP7071329B2 (enExample) |
| KR (1) | KR20190028771A (enExample) |
| CN (1) | CN109715665A (enExample) |
| AR (1) | AR109264A1 (enExample) |
| AU (1) | AU2017299125A1 (enExample) |
| BR (1) | BR112019000770A2 (enExample) |
| CA (1) | CA3030943A1 (enExample) |
| CL (1) | CL2019000119A1 (enExample) |
| CO (1) | CO2019001367A2 (enExample) |
| CR (1) | CR20190072A (enExample) |
| DO (1) | DOP2019000011A (enExample) |
| EA (1) | EA201990321A1 (enExample) |
| EC (1) | ECSP19011185A (enExample) |
| IL (1) | IL264248A (enExample) |
| MA (1) | MA45680A (enExample) |
| MX (1) | MX2019000844A (enExample) |
| PE (1) | PE20190514A1 (enExample) |
| PH (1) | PH12019500122A1 (enExample) |
| SG (1) | SG11201900400QA (enExample) |
| TN (1) | TN2019000015A1 (enExample) |
| TW (1) | TWI790206B (enExample) |
| WO (1) | WO2018015340A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3247725T (lt) | 2015-01-23 | 2020-10-12 | Sanofi | Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| HUE060504T2 (hu) | 2016-02-03 | 2023-03-28 | Amgen Res Munich Gmbh | PSMA és CD3 bispecifikus T-sejthez kötõ ellenanyag-konstrukciók |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| AU2019371243A1 (en) * | 2018-10-30 | 2021-05-27 | Bruker Spatial Biology, Inc. | Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies |
| US12264197B2 (en) | 2019-03-11 | 2025-04-01 | Janssen Biotech, Inc. | Anti-Vβ17/anti-CD123 bispecific antibodies |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| CN111349163B (zh) * | 2020-02-05 | 2024-07-16 | 北京智仁美博生物科技有限公司 | 针对cd123的单克隆抗体 |
| TWI874613B (zh) * | 2020-03-17 | 2025-03-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| BR112023002488A2 (pt) | 2020-08-10 | 2023-05-02 | Janssen Biotech Inc | Materiais e métodos para produzir linfócitos biomodificados contra vírus específicos |
| US11965024B2 (en) | 2020-09-11 | 2024-04-23 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| WO2022144836A1 (en) * | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| EP4294829A4 (en) * | 2021-02-17 | 2025-03-19 | IGM Biosciences Inc. | ANTI-CD123 BINDING MOLECULES AND THEIR USES |
| CN113368232B (zh) * | 2021-06-02 | 2022-08-26 | 上海交通大学 | 多特异性抗原结合蛋白及其应用 |
| JP2024530465A (ja) * | 2021-08-06 | 2024-08-21 | ウニバズィテート バーゼル | 細胞療法に使用するための識別可能な細胞表面タンパク質変異体 |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| EP4665385A2 (en) | 2023-02-17 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| EP0497883B1 (en) | 1989-10-27 | 1998-07-15 | Arch Development Corporation | Compositions and their use for promoting immunopotentiation |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| IL100460A (en) | 1990-12-20 | 1997-06-10 | Ixsys | Method for optimization of binding proteins and nucleic acids encoding a binding protein produced thereby |
| AU6248994A (en) | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0811691B1 (en) | 1995-09-11 | 2004-12-01 | Kyowa Hakko Kogyo Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| CA3036031C (en) | 2000-03-06 | 2021-04-13 | Craig T. Jordan | A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
| WO2009032661A1 (en) | 2007-08-29 | 2009-03-12 | Sanofi-Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2009299791B2 (en) * | 2008-10-01 | 2016-02-25 | Amgen Research (Munich) Gmbh | Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| WO2015086548A1 (en) * | 2013-12-10 | 2015-06-18 | F. Hoffmann-La Roche Ag | Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure |
| UA120060C2 (uk) * | 2014-09-05 | 2019-09-25 | Янссен Фармацевтика Нв | Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування |
| KR102689285B1 (ko) * | 2014-11-26 | 2024-07-31 | 젠코어 인코포레이티드 | Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체 |
| LT3247725T (lt) * | 2015-01-23 | 2020-10-12 | Sanofi | Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
-
2017
- 2017-07-14 TW TW106123588A patent/TWI790206B/zh not_active IP Right Cessation
- 2017-07-17 CR CR20190072A patent/CR20190072A/es unknown
- 2017-07-17 MX MX2019000844A patent/MX2019000844A/es unknown
- 2017-07-17 AU AU2017299125A patent/AU2017299125A1/en not_active Abandoned
- 2017-07-17 CA CA3030943A patent/CA3030943A1/en active Pending
- 2017-07-17 JP JP2019502257A patent/JP7071329B2/ja active Active
- 2017-07-17 TN TNP/2019/000015A patent/TN2019000015A1/en unknown
- 2017-07-17 EP EP17749380.6A patent/EP3484924A1/en not_active Withdrawn
- 2017-07-17 CN CN201780056945.7A patent/CN109715665A/zh active Pending
- 2017-07-17 SG SG11201900400QA patent/SG11201900400QA/en unknown
- 2017-07-17 US US16/318,599 patent/US20190241657A1/en not_active Abandoned
- 2017-07-17 AR ARP170101993A patent/AR109264A1/es unknown
- 2017-07-17 WO PCT/EP2017/068020 patent/WO2018015340A1/en not_active Ceased
- 2017-07-17 BR BR112019000770A patent/BR112019000770A2/pt not_active IP Right Cessation
- 2017-07-17 PE PE2019000065A patent/PE20190514A1/es not_active Application Discontinuation
- 2017-07-17 MA MA045680A patent/MA45680A/fr unknown
- 2017-07-17 KR KR1020197004345A patent/KR20190028771A/ko not_active Withdrawn
- 2017-07-17 EA EA201990321A patent/EA201990321A1/ru unknown
-
2019
- 2019-01-15 IL IL264248A patent/IL264248A/en unknown
- 2019-01-16 CL CL2019000119A patent/CL2019000119A1/es unknown
- 2019-01-16 DO DO2019000011A patent/DOP2019000011A/es unknown
- 2019-01-16 PH PH12019500122A patent/PH12019500122A1/en unknown
- 2019-02-15 EC ECSENADI201911185A patent/ECSP19011185A/es unknown
- 2019-02-15 CO CONC2019/0001367A patent/CO2019001367A2/es unknown
-
2022
- 2022-05-02 JP JP2022075664A patent/JP2022105138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20190514A1 (es) | 2019-04-10 |
| CL2019000119A1 (es) | 2019-06-14 |
| BR112019000770A2 (pt) | 2019-07-02 |
| DOP2019000011A (es) | 2019-05-15 |
| AU2017299125A1 (en) | 2019-03-07 |
| TN2019000015A1 (en) | 2020-07-15 |
| JP2022105138A (ja) | 2022-07-12 |
| IL264248A (en) | 2019-02-28 |
| EP3484924A1 (en) | 2019-05-22 |
| SG11201900400QA (en) | 2019-02-27 |
| TWI790206B (zh) | 2023-01-21 |
| KR20190028771A (ko) | 2019-03-19 |
| CA3030943A1 (en) | 2018-01-25 |
| CN109715665A (zh) | 2019-05-03 |
| CO2019001367A2 (es) | 2019-02-19 |
| EA201990321A1 (ru) | 2019-06-28 |
| CR20190072A (es) | 2019-06-25 |
| PH12019500122A1 (en) | 2019-04-15 |
| TW201811830A (zh) | 2018-04-01 |
| JP7071329B2 (ja) | 2022-05-18 |
| MA45680A (fr) | 2019-05-22 |
| ECSP19011185A (es) | 2019-02-28 |
| US20190241657A1 (en) | 2019-08-08 |
| MX2019000844A (es) | 2019-07-04 |
| JP2019531701A (ja) | 2019-11-07 |
| WO2018015340A1 (en) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| AR095614A1 (es) | Anticuerpos heterodiméricos biespecíficos | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| MD4655B1 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| AR101753A1 (es) | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| UY36536A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| EA201992755A1 (ru) | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) | |
| EA201490020A1 (ru) | Растворимые белки для применения в качестве терапевтических средств | |
| CO6761352A2 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| AR108779A1 (es) | Anticuerpos | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |